Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Francisco Espejo-Porras, Javier Fernández-Ruiz & Eva de Lago. (2018) Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:5-6, pages 377-386.
Read now
Read now
Giulio E. Lancioni, Nirbhay N. Singh, Mark F. O’Reilly, Jeff Sigafoos, Gabriele Ferlisi, Giacomina Ferrarese, Valeria Zullo & Doretta Oliva. (2014) A voice-sensitive microswitch for a man with amyotrophic lateral sclerosis and pervasive motor impairment. Disability and Rehabilitation: Assistive Technology 9:3, pages 260-263.
Read now
Read now
Giulio E. Lancioni, Nirbhay N. Singh, Mark F. O’Reilly, Vanessa A. Green, Gabriele Ferlisi, Giacomina Ferrarese, Valeria Zullo, Simona Schirone & Doretta Oliva. (2013) A man with amyotrophic lateral sclerosis uses a mouth pressure microswitch to operate a text messaging system with a word prediction function. Developmental Neurorehabilitation 16:5, pages 315-320.
Read now
Read now
Michael P Bova & Gene G Kinney. (2013) Emerging drug targets in amyotrophic lateral sclerosis. Expert Opinion on Orphan Drugs 1:1, pages 5-20.
Read now
Read now
Petra Dunkel, Christina LL Chai, Beáta Sperlágh, Paul B Huleatt & Péter Mátyus. (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs 21:9, pages 1267-1308.
Read now
Read now
Giulio E. Lancioni, Nirbhay N. Singh, Mark F. O’Reilly, Gabriele Ferlisi, Ida Blotta, Irene Ricci, Antonella Spica & Doretta Oliva. (2012) A technology-aided program to support leisure engagement and communication by a man with amyotrophic lateral sclerosis. Developmental Neurorehabilitation 15:2, pages 149-153.
Read now
Read now
Articles from other publishers (28)
Donatella Ciarmoli & Fabrizio Stasolla. 2022. Analyzing Multidisciplinary Uses and Impact of Innovative Technologies. Analyzing Multidisciplinary Uses and Impact of Innovative Technologies
69
94
.
Belgin Sever, Halilibrahim Ciftci, Hasan DeMirci, Hilal Sever, Firdevs Ocak, Burak Yulug, Hiroshi Tateishi, Takahisa Tateishi, Masami Otsuka, Mikako Fujita & Ayşe Nazlı Başak. (2022) Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 23:5, pages 2400.
Crossref
Crossref
Carmen Rodríguez‐Cueto, Marta Gómez‐Almería, Laura García Toscano, Julián Romero, Cecilia J. Hillard, Eva de Lago & Javier Fernández‐Ruiz. (2021)
Inactivation of the CB
2
receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis
. Brain Pathology 31:6.
Crossref
Crossref
Samuel S. Duffy, Jessica P. Hayes, Nathan T. Fiore & Gila Moalem-Taylor. (2021) The cannabinoid system and microglia in health and disease. Neuropharmacology 190, pages 108555.
Crossref
Crossref
Danielle Beaulieu, Albert A. Taylor, Dustin Pierce, Jonavelle Cuerdo, Mark Schactman, Mike Keymer & David L. Ennist. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
333
366
.
Qing Xin, Fei Xu, Devin H. Taylor, Jing-fu Zhao & Jie Wu. (2020) The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders. Acta Pharmacologica Sinica 41:12, pages 1507-1518.
Crossref
Crossref
Francisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, Irene Santos-García, Eva de Lago & Javier Fernandez-Ruiz. (2019)
Targeting glial cannabinoid CB
2
receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
. British Journal of Pharmacology 176:10, pages 1585-1600.
Crossref
Crossref
Maria S. Aymerich, Ester Aso, Miguel A. Abellanas, Rosa M. Tolon, Jose A. Ramos, Isidre Ferrer, Julian Romero & Javier Fernández-Ruiz. (2018) Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochemical Pharmacology 157, pages 67-84.
Crossref
Crossref
Carmen Rodríguez-Cueto, Irene Santos-García, Laura García-Toscano, Francisco Espejo-Porras, MLuz Bellido, Javier Fernández-Ruiz, Eduardo Muñoz & Eva de Lago. (2018) Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochemical Pharmacology 157, pages 217-226.
Crossref
Crossref
Paramita Chakrabarty & Jacob I. Ayers. 2018. Gene Therapy in Neurological Disorders. Gene Therapy in Neurological Disorders
229
246
.
Nakul Katyal & Raghav Govindarajan. (2017) Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement. Frontiers in Neurology 8.
Crossref
Crossref
María Fernández-Trapero, Francisco Espejo-Porras, Carmen Rodríguez-Cueto, Joan R. Coates, Carmen Pérez-Díaz, Eva de Lago & Javier Fernández-Ruiz. (2017) Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Disease Models & Mechanisms.
Crossref
Crossref
Javier Fernández-Ruiz, María A. Moro & José Martínez-Orgado. (2015) Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics 12:4, pages 793-806.
Crossref
Crossref
Francisco Espejo-Porras, Fabiana Piscitelli, Roberta Verde, José A. Ramos, Vincenzo Di Marzo, Eva de Lago & Javier Fernández-Ruiz. (2015) Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of Neuroimmune Pharmacology 10:2, pages 233-244.
Crossref
Crossref
Eva de Lago, Miguel Moreno-Martet, Francisco Espejo-Porras & Javier Fernández-Ruiz. 2015. Cannabinoids in Neurologic and Mental Disease. Cannabinoids in Neurologic and Mental Disease
99
123
.
Hiroshi Mitsumoto, Benjamin R Brooks & Vincenzo Silani. (2014) Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?. The Lancet Neurology 13:11, pages 1127-1138.
Crossref
Crossref
Toshio Ariga. (2014) Pathogenic role of ganglioside metabolism in neurodegenerative diseases. Journal of Neuroscience Research 92:10, pages 1227-1242.
Crossref
Crossref
Miguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz & Eva de Lago. (2014)
Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1
G93A
Transgenic Mice and Evaluation of a Sativex
®
-like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis
. CNS Neuroscience & Therapeutics 20:9, pages 809-815.
Crossref
Crossref
Barış Genç & P. Hande Özdinler. (2014) Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discovery Today 19:4, pages 441-449.
Crossref
Crossref
H. Hovden, J. L. Frederiksen & S. W. Pedersen. (2013) Immune system alterations in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, pages n/a-n/a.
Crossref
Crossref
Punna Rao Ravi, Rahul Vats & Upendra Reddy Kora. (2013) Effect of ciprofloxacin and grapefruit juice on oral pharmacokinetics of riluzole in Wistar rats. Journal of Pharmacy and Pharmacology 65:3, pages 337-344.
Crossref
Crossref
Michael P Bova & Gene G Kinney. (2013) Emerging drug targets in amyotrophic lateral sclerosis. Expert Opinion on Orphan Drugs 1:1, pages 5-20.
Crossref
Crossref
D. Michal Freedman, Rochelle E. Curtis, Sarah E. Daugherty, James J. Goedert, Ralph W. Kuncl & Margaret A. Tucker. (2012) The association between cancer and amyotrophic lateral sclerosis. Cancer Causes & Control 24:1, pages 55-60.
Crossref
Crossref
Giulio E. Lancioni, Nirbhay N. Singh, Mark F. O’Reilly, Jeff Sigafoos, Gabriele Ferlisi, Giacomina Ferrarese, Valeria Zullo, Luigi M. Addante, Antonella Spica & Doretta Oliva. (2012) Technology-aided programs for assisting communication and leisure engagement of persons with amyotrophic lateral sclerosis: Two single-case studies. Research in Developmental Disabilities 33:5, pages 1605-1614.
Crossref
Crossref
Isidro Salcedo, David Tweedie, Yazhou Li & Nigel H Greig. (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology 166:5, pages 1586-1599.
Crossref
Crossref
Philip K.-Y. Chang, David Verbich & R. Anne McKinney. (2012) AMPA receptors as drug targets in neurological disease - advantages, caveats, and future outlook. European Journal of Neuroscience 35:12, pages 1908-1916.
Crossref
Crossref
Yazhou Li, Srinivasulu Chigurupati, Harold W. Holloway, Mohamed Mughal, David Tweedie, Daniel A. Bruestle, Mark P. Mattson, Yun Wang, Brandon K. Harvey, Balmiki Ray, Debomoy K. Lahiri & Nigel H. Greig. (2012) Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS ONE 7:2, pages e32008.
Crossref
Crossref
Miguel Moreno-Martet, Leyre Mestre, Frida Loría, Carmen Guaza, Javier Fernández-Ruiz & Eva de Lago. (2012) Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters 508:2, pages 67-72.
Crossref
Crossref